Baxter/Halozyme Hyaluronidase Enhanze SC Set For Approval By September
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Halozyme human-derived hyaluronidase Enhanze SC user fee goal is September 23 following March 23 NDA submission for use as spreading agent. Firm is highlighting greater purity than animal-derived hyaluronidase products. Baxter to market product, provide fill/finish services